+351 211 369 829 INFO@OPHIOMICS.COM

Ophiomics is now participating in the IPOready program by Euronext. This is a great opportunity to consider the best strategy to achieve our ambition to have a global impact in the world of Cancer Precision Medicine

Share the Post:

Related Posts